Peers and Perspectives
Rare Disease Report
Rare Disease Report
View All Conferences
2019 American Academy of Dermatology Annual Meeting
The AAD Annual Meeting is a conglomeration of the largest, most influential representative dermatology group of 20,000-plus in the US, as well as an increasing number of international specialists.
Neal Walker, MD: Investigating a Topical Treatment for Warts
There are currently no FDA-approved prescription treatments for common warts, instead dermatologists must rely on painful alternatives like cutting, burning, and freezing.
Patrick Burnett, MD, PhD: Pipeline Progress of VP-102 for Molluscum Contagiosum
Following the completion of 2 pivotal trials, a new drug application for VP-102 will be submitted later this year.
Simon Murray, MD: Diagnosis and Treatment of Onychomycosis
Onychomycosis—fungal infection of the nail—is a common medical problem. Treatments are widely available, but relapse is common.
Larry Green, MD: Efficacy of Halobetasol & Tazarotene Lotion
In a post hoc analysis, Green and colleagues examined the effect of halobetasol and tazarotene lotion on plaque psoriasis in a Hispanic population.
Larry Green, MD: Halobetasol & Tazarotene Lotion in a Hispanic Population
Green introduces the combination lotion tested in this clinical trial of patients with moderate-to-sever plaque psoriasis.
Simon Murray, MD: AAD Recommendations for Acne Treatment
Recommendations for acne treatment drawn from AAD position paper and presentations.
Ken Gordon, MD: Role of Placebo in the UltIMMa Trials
Even in trials like UltIMMA that compare 2 drugs, a placebo control grounds the data, says Ken Gordon, MD.
James Q. Del Rosso, DO: Unlocking Isotretinoin's Benefits
The nodular acne therapy has been a staple treatment for 3 decades, yet new AAD data showed it could still be better utilized in patients.
John Durkin, MD: Confocal Microscopy and its Benefits
Confocal microscopy is an emerging technique that can offer a non-invasive alternative to biopsy.
Hyperhidrosis Associated with Higher Anxiety, Depression, ADD
The prevalence of anxiety, depression, and ADD was higher in patients with this excessive sweating disorder than the general population.
Lidose-Isotretinoin Sustains Long-Term Acne Benefit Without Food Intake
A new, long-term assessment of phase 4 data shows a twice-daily regimen of the common acne therapy can retain patient benefits weeks after treatment ends.
Ken Gordon, MD: Clinical Implications of the UltIMMa Trials of Risankizumab
Aside from the efficacy and safety of risankizumab, Gordon addresses the convenience, ease of use, and persistence of efficacy for patients with psoriasis.
Melinda Gooderham, MD: Clinical Implications of the reSURFACE 2 Trial
Gooderham addresses what the 3-year results of the reSURFACE 2 trial of tildrakizumab for plaque psoriasis mean for prescribers.
Ken Gordon, MD: Insights on Risankizumab for Plaque Psoriasis
The analysis of the UltIMMa 1 & 2 trials of risankizumab demonstrated efficacy and safety in the treatment of moderate-to-severe plaque psoriasis.
Dedee Murrell, MD: Results of the Believe-PV Pemphigus Vulgaris Trial
Investigational treatment PRN1008 demonstrated efficacy in this difficult-to-treat condition.
Melinda Gooderham, MD: 3-Year Results of the reSURFACE 2 Trial
This extension study investigated the long-term efficacy and safety of tildrakizumab for patients with plaque psoriasis.
Tildrakizumab Improves Psoriasis Patient Quality of Life
Results from the reSURFACE 1 phase 3 trial shows the biologic is beneficial to patient rates of anxiety, pain, and depression.
Patrick Burnett, MD, PhD: More Data from CAMP 1 & 2
Patrick Burnett shares about the secondary endpoints and safety data of the CAMP 1 & 2 clinical trials.
Dedee Murrell, MD: Safety of PRN1008 for Pemphigus Vulgaris
The phase 2 Believe-PV study observed few adverse events in patients with pemphigus vulgaris.
Patrick Burnett, MD, PhD: Results of CAMP 1 & 2 in Molluscum Contagiosum
Patrick Burnett reports impressive topline results from the CAMP 1 & 2 studies of investigational treatment VP-102.
Dedee Murrell, MD: Significance of the Believe-PV Trial in Pemphigus Vulgaris
Though there are few treatments for pemphigus vulgaris, a rare disease, the Believe-PV trial of PRN1008 raises the possibility of a new, better option.
Ixekizumab Sustains Plaque Psoriasis Severity Improvement Over 1 Year
Investigators assessed patients’ scores for body surface area, static Physician Global Assessments, and Dermatology QoL Index at 1 month post-index, and at three-month intervals both pre- and post-index.
Hemali Gunt, PhD: Adjunctive Skin Care for Rosacea
Compared to standard cleansers and moisturizers, natural versions for sensitive skin provided benefits to patients with rosacea who were also taking prescription treatments.
Jeffrey Weinberg, MD: Psoriasis Duration Doesn't Impact Brodalumab Success
In this analysis, brodalumab was successful in treating patients who had a psoriasis diagnosis for <1 to ≥10 years.
Study: Tildrakizumab Among Most Cost-Effective Plaque Psoriasis Therapies
New data from AAD show the recently-approved biologic is among the most cost-saving therapies in year 2 of treatment, and beyond.
Dupilumab Improves Atopic Dermatitis Patient Quality of Life
Investigators sought to evaluate the efficacy, safety, psychosocial impact, quality of life, adherence to and satisfaction with the treatment of dupilumab and add-on treatment.
Simon Murray, MD: AAD 2019 Sessions to Attend
An internist’s perspective on which sessions to attend, from melanoma to inflammatory diseases to cosmetic procedures.
Platelet-rich Plasma Improves Hair Loss, Scars, and More
A meta-analysis of studies found that treatment with platelet-rich plasma improves androgenetic alopecia, scarring, and other dermatologic conditions.
Isotretinoin Not Associated with Depression Risk for Acne Patients
A large retrospective study of patients with acne found no significant association between isotretinoin exposure and depression.
Pediatric Primary Care Visits Declining Since 2008
How to Spot a Bad Doctor
FDA Approves Teprotumumab for Thyroid Eye Disease
FDA Approves Cocaine Hydrochloride Nasal Anesthetic Solution
Overview of Sickle Cell Disease
Affordable Care Act
PHYSICIAN'S MONEY DIGEST >
MD Magazine Resources
Terms & Conditions
Copyright© MD Magazine 2006-2020 Intellisphere, LLC. All Rights Reserved.